HUTCHMED (China) 株価情報 (NASDAQ: HCM)

最新ニュース HUTCHMED (China) (NASDAQ:HCM) 株価情報

HUTCHMED (China)

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China) Ltd

HCM ACQUISITION CORP USD CL A ORD SHS

HCM ACQUISITION CORP USD UNITS CONSISTING ONE CL A ORD SH OF $0.0001 PAR VALUE &

HCM ACQUISITION CORP USD RED WTS

HEALTHIER CHOICES MGMT by Healthier Choices Management Corp.

Healthier Choices Management Corp

Holcim Ltd

Direxion Shares ETF Trust Direxion HCM Tactical Enhanced US ETF

Bitcoin Cash (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bch/usd">BCH</a>) has soared 15% to $486.71 this week, riding the wave of investor enthusiasm across the <a href="https://www.benzinga.com/crypto">cryptocurrency</a> market. 
The rally coincides with heightened activity in the broader crypto space, particularly Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) drive toward record highs, as well as favorable speculation about November's performance for leading cryptocurrencies.
What To Know: Bitcoin's all-time high of $98,310 and the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42114012/bitcoin-price-hitting-100000-in-november-polymarket-traders-speculate-it-might-go-even-higher">ensuing predictions</a> of it potentially surpassing $100,000 have reignited interest in its offshoot, Bitcoin Cash. BCH often benefits from Bitcoin's momentum, as investors view it as a faster and more cost-effective alternative for transactions.
Additionally, Bitcoin Cash's rise comes amidst strong institutional inflows into Bitcoin-related assets, such as spot ETFs, which recorded $1.84 billion in net inflows in the past three days. The enthusiasm for Bitcoin appears to be trickling down to its derivative projects, including BCH.
The rally could also be attributed to Bitcoin Cash's appeal as a practical digital currency, aligning with growing use-case narratives as global monetary policies ease. 
Recent network upgrades to improve BCH's scalability and transaction efficiency have bolstered its utility, making it potentially an attractive asset in a bullish environment.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42114875/coinbase-ceo-brian-armstrong-stands-out-as-candidate-for-donald-trumps-reported-crypto-czar-position-cardano-co-founder-says">Coinbase CEO Brian Armstrong &#8216;Stands Out&#8217; As Candidate For Donald Trump&#8217;s Reported &#8216;Crypto Czar&#8217; Position, Cardano Co-Founder Says</a>

News

$BCH

$BTC

Why Bitcoin Cash Is Up 15% This Week

TD Cowen analyst Phil Nadeau reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Buy.

Reiteration

Analyst Ratings

KURA

TD Cowen Reiterates Buy on Kura Oncology

Bernie Sanders has often been criticized for owning three houses and having a net worth of around $2 million, especially by those on the right who call out his <a href="https://www.benzinga.com/startups/24/10/41303029/id-still-have-1-3-billion-bill-gates-says-bernie-sanders-would-take-99-of-his-fortune-he-claims-hed">stance on wealth inequality</a>. But Sanders has a simple explanation for his wealth and shared his thoughts during an appearance on the Lex Fridman <a href="https://www.youtube.com/watch?v=miWJinIlMjc">Podcast</a>.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
</ul>
&#8220;Do I own three residences? Yeah, I do,&#8221; Sanders said. He explained that he lives in Burlington, Vermont, in a &#8220;middle-class neighborhood, nice house,&#8221; and owns another home in Washington, D.C., like most senators do. He also has a summer camp on Lake Champlain. &#8220;That&#8217;s it,&#8221; Sanders stated, noting that his homes are far from luxurious. &#8220;They&#8217;re middle-class houses.&#8221;
When asked how he managed to afford these properties, Sanders pointed to his success as an author. &#8220;I wrote two bestselling books,&#8221; he said, including one about capitalism that became a New York Times bestseller. He also earns $175,000 a year as a senator.
Sanders emphasized that while he&#8217;s now comfortable financially, his working-class background remains a key part of who he is. &#8220;Growing up in a working-class family has been maybe the most singularly significant aspect of my politics,&#8221; he said. He grew up in a rent-controlled apartment in Brooklyn and remembers not having money.
See Also: This rooftop wind turbine is taking on a market projected to reach over $900 billion by 2032 —<a href="https://www.benzinga.com/money/halcium"> With already over 40,000 users signing up to purchase, here's a chance to be an early investor today!</a>
&#8220;I don&#8217;t really give a damn about money,&#8221; he added. Sanders drives an 11-year-old car, wears a solar-powered watch and owns a simple wedding ring – no luxury goods. &#8220;I don&#8217;t have a Rolex watch, would not be interested in it,&#8221; he said. For Sanders, money isn&#8217;t about status; it&#8217;s about security.
&#8220;The major thing about having money … I don&#8217;t have to worry if somebody in my family gets sick. I don&#8217;t have to worry about putting food on the table or paying the mortgage,&#8221; he explained. Sanders noted how this lack of <a href="https://www.benzinga.com/personal-finance/24/07/39988774/survey-finds-nearly-half-of-people-say-2024-is-the-most-stressful-year-financially-94-admit-sacr">financial stress</a> is a luxury and he&#8217;s aware of how different that is from the experience of <a href="https://www.benzinga.com/real-estate/24/06/39274689/amid-rising-costs-financial-strain-becomes-americas-chief-anxiety">many working-class Americans</a>.
Sanders also discussed how easy it is for politicians to lose touch with everyday struggles: &#8220;It&#8217;s a very easy trap to fall into – you can get separated from ordinary people and their struggles,&#8221; he admitted. By frequently working directly with members of the working class and endorsing labor strikes, he tries to stay grounded.
Despite his financial comfort, Sanders remains focused on fighting for the working class. &#8220;I do my best,&#8221; he said, adding that having wealth doesn&#8217;t mean he&#8217;s forgotten where he came from or the struggles he faced earlier in his life.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/advisor-adv-warren-buffett">Warren Buffett Flipped His Neighbor's $67,000 Life Savings Into A $50 Million Fortune — This Would Be Worth Over $500 Million Today</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>
Image from Shutterstock

Bernie Sanders Says It's 'Very Easy' To Lose Touch With Ordinary People's Struggles, Defends Owning 3 Houses And A $2 Million Net Worth

<h4>Key Takeaways:</h4>
<ul>
<li>RLX&rsquo;s third quarter revenue rose 52%, as its gross margin rose more than 3 percentage points to 27.2% following a regulatory crackdown in 2021</li>
<li>A year after expanding beyond its China base, international business accounted for more than half of the vaping company&rsquo;s revenues in the third quarter</li>
</ul>
By Edith Terry
Vaping may not be as hazardous to your health as smoking, but it was quite the damper for&nbsp;RLX Technology Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rlx#NYSE">RLX</a>) when the company was doused by a massive wave of new regulation in 2021 in its home China market. Now, three years later, the company may finally be turning a corner, capitalizing on a globalization strategy where it&rsquo;s finding success using a combination of strong brand recognition and its own deep pockets.
Non-China business in five countries in East Asia, Southeast Asia and Oceania accounted for more than half of the company&rsquo;s revenues in the third quarter, said Sam Tsang, RLX&rsquo;s head of capital markets, on the company&rsquo;s earnings call after the release of its&nbsp;<a href="https://www.prnewswire.com/news-releases/rlx-technology-announces-unaudited-third-quarter-2024-financial-results-302305299.html">third-quarter results</a>&nbsp;last week.
That&rsquo;s quite a feat when one considers the company only posted its first international sales of 228.5 million yuan starting last year, when that category made up 17% of revenues for the year. The company is also considering additional markets in 2025, either in the Middle East or Central America, Tsang added.
&ldquo;Based on our internal estimates, we are currently the number one brand in three out of five countries in terms of revenue from the closed system e-vapor category,&rdquo; he said. &ldquo;We are also one of the leading brands in the remaining two countries. We also sell products to affiliates that sell to their overseas distributors.&rdquo;
Its strong overall performance for the quarter was enough to catch the attention of investors, who bid up RLX&rsquo;s shares by 9.3% in the five days after the quarterly report&rsquo;s release. And in a show of confidence about its prospects, the company announced it would pay a dividend in December.
RLX&rsquo;s main metrics were all quite hot in the latest quarter. Its revenue rose 52% year-on-year to 756.3 million yuan, marking a sixth consecutive quarter of growth. With revenue of 1.9 billion yuan in the first nine months of this year, RLX is already well ahead of the 1.5 billion yuan it generated for all of last year, though it&rsquo;s still well off the 8.5 billion yuan it clocked during its heyday in 2021.
That was the year China abruptly banned online sales of vaping devices, followed by a subsequent ban on flavored vapes that appealed to the youth market and imposition of a 36% sales tax on all vaping products.
The company&rsquo;s gross margin also rose to 27.2% in the latest quarter from 24.1% a year earlier. Its quarterly net income for the third quarter fell slightly year-on-year to 169.4 million yuan. But its non-GAAP profit, which excludes some non-operational factors like stock-based employee compensation, rose 30% year-on-year to 261.9 million yuan.
Tsang&rsquo;s disclosure that more than half of RLX&rsquo;s revenue came from outside China means the company got less than 378 million yuan from the domestic market during the period. That shows the domestic market is still suffering, since RLX recorded 498.9 million yuan in revenues in the third quarter of 2023, most of that probably from China.
<h3>Rebuilding China Business</h3>
The company has previously said it is still rebuilding its China business under the tighter post-crackdown restrictions. It has also complained that it faces competition from illegal products that may, for example, still use flavorings favored by many users.
On the earnings call, Tsang said retail outlets in China had declined from 50,000 in the pre-crackdown era to just 10,000, and reiterated that the flood of illegal products had taken down sales for the compliant industry by 80% to 90%. But he added that sales for products at a range of price points had started stabilizing this year.
RLX has been somewhat late jumping onto the export bandwagon. China produces as much as 95% of the world&rsquo;s vaping products, but 90% of those are exported. Grand View Research estimated the China e-cigarette and vape market was worth $2.27 billion in 2023, equal to just 9% of the $24.6 billion in global sales that year estimated by data aggregator Statista. RLX competitors like&nbsp;Ispire Technology&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ispr#NASDAQ">ISPR</a>) and&nbsp;Smoore International&nbsp;(6969.HK) both derive significant revenues from selling to markets outside China.
RLX&rsquo;s sales were all in China until late 2023. It joined forces with the government in China to combat illegal products that were a big factor in depressing sales, with its Golden Shield program helping to intercept 60 million fake cartridges in 2023. CEO Wang Ying, who also uses the name Kate, said on the earnings call that between 80% and 90% of products sold in China were illegal. While the counterfeit problem may be easing this year, RLX isn&rsquo;t waiting for the market to rebound and instead is diversifying geographically to fortify its business.
To kick off its global drive, it announced $25 million in equity investments in two companies in Northeast Asia and Southeast Asia last December. So far it has yet to enter the large but similarly tricky U.S. market, which has engaged in its own regulatory crackdowns and is also clamping down on a flood of illegal vaping devices.
RLX has spent millions of dollars on U.S. Food and Drug Administration-required studies since 2020 but has yet to receive approval for its devices. While it has not revealed which specific markets it has entered or is targeting, it has distribution in Indonesia, which has a smoking population of 61.4 million &ndash; far more than 28.3 million in the U.S. though tiny compared to China&rsquo;s 300 million smokers.
While estimates of prospects for the global vaping market vary widely, most agree it is growing by double digits. RLX CEO Wang concurred, saying the international industry should experience annual growth in the teens percentage range over the next few years as more adult smokers transition from cigarettes to vaping products.
Despite all the beating it&rsquo;s taken over the last three years, RLX&rsquo;s price-to-sales (P/S) ratio of 8.81 is still far ahead of Ispire&rsquo;s 3.06, probably due to the fact that Ispire is losing money and its revenue is falling.
Ispire also reported last week that its revenue declined by 9% year-on-year to $39.3 million in the three months to September, while its net loss widened to $5.6 million from $1.3 million. One thing Ispire shares with RLX is its search for new markets, as it tries to expand beyond the U.S. where its sales plunged by more than half in the latest quarter to $8.1 million. That just goes to show that the U.S. and China may be the world&rsquo;s two largest economies, but they&rsquo;re hardly friendly to vaping companies.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Penny Stocks

Small Cap

ISPR

Rebounding RLX Plots Course Beyond China

By <a href="https://roboforex.com/beginners/analytics/forex-forecast/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_21112024&amp;utm_content=analysis&amp;utm_term=forecast" style="color:#0563c1; text-decoration:underline">RoboForex Analytical Department</a>
The NZD/USD pair is trading near 0.5879, experiencing volatility as the market awaits the upcoming Reserve Bank of New Zealand (RBNZ) meeting. Expectations are leaning towards a significant rate cut, with a 50-basis-point reduction considered the baseline scenario and a 25% probability of a more aggressive 75-basis-point cut.
Adding to the uncertainty are pessimistic projections from the New Zealand Treasury, suggesting potential delays in economic recovery, further weighing on sentiment around the NZD.
Internally, the US dollar&rsquo;s strength, fuelled by mixed expectations regarding the Federal Reserve&rsquo;s policy decisions in December, continues to exert substantial pressure on the NZD. Since the US election, the dollar has emerged as a dominant force, benefiting from robust domestic factors, and overshadowing other currencies that lack similar support, leading to their devaluation. As a result, the NZD, particularly vulnerable, reflects this broader depreciation trend against the USD.
<h3>Technical Analysis Of NZD/USD</h3>
<a href="https://www.benzinga.com/files/u117641/nzdusdh4_14.png"><img alt="" src="https://www.benzinga.com/files/u117641/nzdusdh4_14.png" style="height:280px; width:624px" /></a>
On the H4 chart of NZD/USD, the market corrected to the 0.5921 level. Today, a decline wave structure is forming at the 0.5858 level, marking the boundaries of the consolidation range. A downward exit from this range could indicate the potential for the wave to extend towards 0.5777. Alternatively, an upward exit may result in another corrective move towards 0.5944 before the price resumes its decline to 0.5777.&nbsp; From a technical standpoint, this bearish outlook for NZD/USD is supported by the MACD indicator, with its signal line below zero and sloping downward.
<a href="https://www.benzinga.com/files/u117641/nzdusdh1_14.png"><img alt="" src="https://www.benzinga.com/files/u117641/nzdusdh1_14.png" style="height:280px; width:624px" /></a>
On the H1 chart of NZD/USD, the market has formed a consolidation range around 0.5875. Today, another decline wave towards 0.5777 is likely to develop. At this level, the wave is expected to exhaust its downside potential. This scenario is technically confirmed by the Stochastic oscillator, with its signal line below 50 and trending downward.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

NZD/USD Under Pressure Amidst USD Strength

Evercore ISI Group analyst Michael Binetti maintains TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) with a Outperform and raises the price target from $138 to $142.

Price Target

Evercore ISI Group Maintains Outperform on TJX Companies, Raises Price Target to $142

Scotiabank analyst Tanya Jakusconek upgrades Anglogold Ashanti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) from Sector Underperform to Sector Perform and maintains the price target from $30 to $30.

Upgrades

Scotiabank Upgrades Anglogold Ashanti to Sector Perform, Maintains Price Target to $30

BTIG analyst Gray Powell maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and raises the price target from $395 to $414.

PANW

BTIG Maintains Buy on Palo Alto Networks, Raises Price Target to $414

Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.13 by 15.38 percent. This is a 87.36 percent decrease over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $684.28 million which missed the analyst consensus estimate of $694.22 million by 1.43 percent. This is a 4.42 percent decrease over sales of $715.90 million the same period last year.

Earnings

Earnings Misses

VSTS

Reported Earlier, Vestis Q4 Adj $0.11 Misses $0.13 Estimate, Sales $684.28M Miss $694.22M Estimate

Evercore ISI Group analyst Greg Melich maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a In-Line and lowers the price target from $165 to $130.

Evercore ISI Group Maintains In-Line on Target, Lowers Price Target to $130

Scotiabank analyst Tanya Jakusconek upgrades Compañía de Minas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BVN#NYSE">BVN</a>) from Sector Underperform to Sector Perform and maintains the price target from $15 to $15.

Scotiabank Upgrades Compañía de Minas to Sector Perform, Maintains Price Target to $15

Benchmark analyst Mark Zgutowicz maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and raises the price target from $225 to $250.

Benchmark Maintains Buy on Wix.com, Raises Price Target to $250

On November 20, 2024, the Board of Directors of United Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBCP#NASDAQ">UBCP</a>) declared a fourth quarter dividend payment of $0.18 per share for shareholders of record on December 10, 2024 with a payment date of December 20, 2024. This payment is greater than the regular cash dividends paid in the first three quarters of the current year, which were $0.1725, $0.1750 and $0.1775 respectively. With this fourth quarter dividend payment and year-to-date, UBCP has paid total cash dividends of $0.8550 (inclusive of a special cash dividend of $0.15 paid in the first quarter), which is an increase of $0.04, or 4.9%, over the amount paid during the same period the previous year. At the fourth quarter payment level, the regular cash dividend produces a forward yield of 5.4% based on UBCP&#39;s market value of $13.13 at the most recent quarter-end.

Dividends

UBCP

United Bancorp Increases Its Q4 Cash Dividend Payment From $0.1775 To $0.18 Per Share

Deutsche Bank analyst Brad Zelnick maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $180 to $190.

SNOW

Deutsche Bank Maintains Buy on Snowflake, Raises Price Target to $190

The contract gives the nation's oldest bank access to more than $3 billion in deposits a month.
 <a href="https://www.americanbanker.com/payments/news/bny-gains-treasurys-direct-express-benefits-contract" title="https://www.americanbanker.com/payments/news/bny-gains-treasurys-direct-express-benefits-contract">https://www.americanbanker.com/payments/news/bny-gains-treasurys-direct-express-benefits-contract</a>

'BNY gains Treasury's Direct Express benefits contract' - American Banker

Citigroup analyst Fatima Boolani maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and raises the price target from $395 to $432.

Citigroup Maintains Buy on Palo Alto Networks, Raises Price Target to $432

Deutsche Bank analyst Brad Zelnick maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and raises the price target from $395 to $415.

Deutsche Bank Maintains Buy on Palo Alto Networks, Raises Price Target to $415

Citigroup analyst Keith Horowitz maintains Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) with a Buy and raises the price target from $50 to $58.

Citigroup Maintains Buy on Citizens Financial Group, Raises Price Target to $58

&nbsp;Fox Entertainment and Hulu are staying in business together in a major way.
The two companies have struck a new multi-year content partnership that includes in-season streaming rights for Fox's programming slate.
The broadcast network and the Disney-owned streamer have also expanded their multi-platform marketing arrangement in the deal, which Deadline understands is worth more than $1.5B over four years with the ad-load included.
Fox got in early to renew the deal – the previous arrangement was unveiled in January 2023 and this new pact runs through 2029. It gives the network a bedrock to build out its slate of originals including dramas such as Rescue HI-Surf and Murder in a Small Town, comedies such as Animal Control and reality series such as The Masked Singer, The Floor and Gordon Ramsay's Next Level Chef.
<a href="https://deadline.com/2024/11/fox-hulu-streaming-deal-1236183347/" title="https://deadline.com/2024/11/fox-hulu-streaming-deal-1236183347/">https://deadline.com/2024/11/fox-hulu-streaming-deal-1236183347/</a>

FOXA

'Fox Entertainment & Hulu Extend Major Streaming Deal With Pact Worth North Of $1.5B' -Deadline

Georgia lawmakers are exploring the <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">potential of psychedelics</a> in treating veterans' mental health challenges, marking a significant shift in the state's traditionally conservative stance on drug policy. As Medical Xpress <a href="https://medicalxpress.com/news/2024-11-georgia-lawmakers-funding-psychedelics-veterans.html">reported</a>, a bipartisan panel has recommended allocating up to $5 million to study the therapeutic effects of substances like <a href="https://www.benzinga.com/topic/mdma">MDMA</a> and <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> on post-traumatic stress disorder (PTSD) and traumatic brain injuries in veterans.
<h3 class="wp-block-heading">A Promising, Yet Controversial Step</h3>
The recommendation is part of 16 proposals from the Senate Study Committee on Veterans, Mental Health and Housing. While funding must still be approved by the Georgia General Assembly, the panel's endorsement reflects growing interest in alternative therapies for PTSD, a condition <a href="https://www.benzinga.com/24/11/41881842/why-do-veterans-deserve-access-to-psychedelic-therapy">disproportionately affecting veterans</a>. Symptoms such as severe anxiety, nightmares, and insomnia often resist traditional treatments, leaving many searching for solutions.
"Veterans who suffer from post-traumatic stress and brain injuries have very few reliable options for treatment," said state Sen. Josh McLaurin, a Democrat from Atlanta and committee member. "A growing body of research shows that psychedelics—when administered carefully in clinical settings—may be a total game changer."
<h3 class="wp-block-heading">National Context and Growing Support</h3>
Georgia's initiative follows similar efforts in states like <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">Oregon</a> and <a href="https://www.benzinga.com/markets/cannabis/24/08/40445352/colorados-psilocybin-industry-takes-off-new-rules-for-magic-mushroom-businesses">Colorado</a>, where psilocybin has been legalized, and California, which narrowly missed passing a psychedelics decriminalization bill last year. Research institutions like Atlanta's Emory University have already begun studying the therapeutic potential of psychedelics when combined with psychotherapy. Despite federal regulators <a href="https://www.benzinga.com/markets/cannabis/24/08/40300943/fda-rejects-mdma-for-ptsd-treatment-calls-for-more-research-on-psychedelic-therapy">recently denying MDMA's approval for PTSD treatment</a>, the U.S. Department of Veterans Affairs (VA) has <a href="https://www.benzinga.com/markets/cannabis/24/01/36523540/veterans-affairs-after-decades-will-fund-psychedelic-research-for-vets-with-ptsd-and-depression">signaled readiness to incorporate psychedelic therapy</a> if it gains regulatory approval.
Support for psychedelic research is also gaining momentum from influential figures like Vietnam veteran and GoDaddy founder Bob Parsons, who has invested millions into advancing the field. His advocacy has swayed skeptics like Democratic state Sen. Ed Harbison who admitted initial hesitation but now sees the potential benefits.
<h3 class="wp-block-heading">Broader Recommendations for Veterans</h3>
The committee's proposals extend beyond psychedelics, including measures to waive or reduce property taxes for returning veterans and establish programs to simplify the complexities of the healthcare system for service members.
If approved, Georgia's research funding would signal an important step toward innovative mental health treatments, offering hope to veterans seeking relief from debilitating conditions. The move reflects a broader national conversation about the role of psychedelics in addressing mental health crises.
Cover image made with AI

Cannabis

Government

Psychedelics

Health Care

Georgia Lawmakers Take First Steps Toward Psychedelic-Assisted Therapy For Veterans

Hutchison China MediTech GAAP ADS of $0.15, revenue of $305.68M

HUTCHMED (China) Limited 2024 Q2 - Results - Earnings Call Presentation

HUTCHMED (China) Limited (HCM) Q2 2024 Earnings Call Transcript

HUTCHMED (HCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Paul Choi from Goldman Sachs...

Hold Rating on HUTCHMED Amid Promising U.S. Launch and Pending EU Reimbursement Clarity

HUTCHMED (China) Limited (HCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on August 2. Analyst Jill W...

Robust Sales and Expansion Potential Underpin Buy Rating for HUTCHMED

Hutchmed Growing Sales By 64% In H1 2024

HUTCHMED pulls regulatory submission for Takeda-partnered cancer drug in China

Chinese biotechs gain as drugmakers targeted in new security bill said to mull divestments

Hutchmed (HCM) announced that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies...

Hutchmed announces new, updated data from sovleplenib ESLIM-01 trial

Global companies with at least 50% U.S. revenue exposure as Trump eyes tariffs: BofA

ARGX

BGNE

BRDCY

FUJHY

HMDCF

IMAB

KWEB

LEGN

LNVGY

MCHI

SVNDY

UPRO

WUXIF

WXIBF

WXXWY

ZLAB

Press Releases

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

General

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

Contracts

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

Opinion

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

Comments

HUTCHMED (China)

ニュース

最新ニュース HUTCHMED (China) (NASDAQ:HCM) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル